| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01738672 Details | 2017-11-21 Interventional | 2 | 16 | Entonox Nitrous Oxide Labor Pain | - The study was limited by its small size. Additionally, because all participants were recruited from Family Medicine clinics in Pittsburgh, these results may not be generalizable to other populations of pregnant women. | |||
| NCT01334710 Details | 2017-11-21 Interventional | 2 | 3 | Sorafenib Carcinoma, Hepa… Liver Neoplasms Liver Cancer | safety issue observed on another hepatocellular study using OSI906 A second trial evaluating OSI906 in hepatocellular cancer was being run in parallel to this trial. There were safety signals in the second trial which led to stopping this trial. | |||
| NCT00194883 Details | 2017-11-21 Interventional | 4 | - | Hormones Renal Insuffici… Renal Insuffici… Chronic Renal I… | - - | |||
| NCT02899026 Details | 2017-11-20 Interventional | 3 | 0 | Antibodies, Mon… Prednisone Giant Cell Arte… Polymyalgia Rhe… | GSK decision to return rights to sirukumab to Janssen and discontinue sirukumab development in
polymyalgia rheumatica. - | |||
| NCT02515851 Details | 2017-11-20 Interventional | 4 | 30 | Bupivacaine Radius Fracture… Wrist Fractures Distal Radius F… | Unable to find sufficient drug naive patients - | |||
| NCT00524589 Details | 2017-11-20 Interventional | 2 | 18 | Calcitriol Dexamethasone Prostatic Neopl… Prostate Cancer | closed due to futility - | |||
| NCT03261596 Details | 2017-11-17 Interventional | 4 | 0 | DMP 777 Mebendazole Piperazine Piperazine citr… Ancylostomiasis Communicable Di… Hookworm Infect… Infections | In light of new evidence, the decision was made by the sponsor to not proceed. - | |||
| NCT02128841 Details | 2017-11-17 Interventional | 2 | 12 | Rivaroxaban Aortic Valve Di… Anticoagulants Heart Valve Pro… | not enough patients - | |||
| NCT01231555 Details | 2017-11-17 Interventional | 2 | 23 | Efavirenz Acquired Immuno… HIV Infections Immunologic Def… Infections Infection, Huma… | - - | |||
| NCT01199731 Details | 2017-11-17 Interventional | 2 | 30 | Etravirine Acquired Immuno… HIV Infections Infections Infection, Huma… | The study was stopped due to safety concerns Enrollment in this study was terminated prematurely on 01 April 2011 due to a safety finding (convulsion) in 5/20 participants receiving GSK2248761. | |||
| NCT00825227 Details | 2017-11-17 Interventional | 2 | 10 | Modafinil Fatigue Chemotherapy Si… | - This trial was discontinued early after only 10 of 160 planned subjects had been recruited. No efficacy data was analyzed. | |||
| NCT00334646 Details | 2017-11-17 Interventional | 1 | 25 | Casopitant Cyclophosphamid… Nausea Vomiting Nausea and Vomi… | compound terminated - | |||
| NCT02556333 Details | 2017-11-14 Interventional | 2 | 1 | Emtricitabine Tenofovir HIV | - The study was approved in late 2015, with the first and only patient enrolled in Jan 2016. The drug was approved in April 2016, which resulted in termination of the protocol. | |||
| NCT01777737 Details | 2017-11-14 Interventional | 3 | 3 | Trimethoprim, S… Fibrosis Idiopathic Pulm… Pulmonary Fibro… | Changes in standards of care - | |||
| NCT00622401 NCT00731406 Details | 2017-11-14 Interventional | 1/2 | 8 | Interleukin-12 Vaccines Breast Neoplasm… Breast Cancer | - In the conduct of the study, it became apparent that the setting of advanced breast cancer with malignant effusions/ascites for vaccine generation was a difficult setting for evaluation of an immune based therapy. | |||
| NCT00158886 Details | 2017-11-14 Interventional | 1 | 26 | Topotecan Carcinoma, Rena… Rectal Neoplasm… | - - | |||
| NCT01748162 Details | 2017-11-13 Interventional | 3 | 10 | Fluticasone Prednisolone Croup Laryngitis | - - | |||
| NCT01066000 Details | 2017-11-13 Interventional | 4 | 33 | Epoetin Alfa Anemia | - This was an open-label, single arm study with no control arms for comparison of results from this study. The study was prematurely terminated due to high screening failures and low recruitment rate. Therefore, the data only showed a trend. | |||
| NCT00570674 Details | 2017-11-13 Interventional | 1/2 | 29 | Albumin-Bound P… Carboplatin Cetuximab Paclitaxel Carcinoma Carcinoma, Aden… Carcinoma, Squa… Head and Neck N… Squamous Cell C… Adenosquamous C… Basaloid Squamo… Squamous Cell C… Undifferentiate… | The study did not continue to phase II due to the importance of HPV status as a prognostic
factor to guide treatment decisions. The phase II portion planned to enroll 34 participants including the expansion cohort but the study did not continue beyond phase I given the importance of HPV status as a prognostic factor to guide treatment decisions. | |||
| NCT00490568 Details | 2017-11-13 Interventional | 3 | 1461 | Rosiglitazone Alzheimer Disea… Alzheimer's Dis… | Based on preliminary parent study results - |